BCAN's Patient Handbook - Bladder Cancer Basics for the Newly Diagnosed



Donate Now to Support the Bladder Cancer Advocacy Network



Join The Online Bladder Cancer Support Community



The Bladder Cancer Advocacy Network (BCAN) is proud to announce that we have been designated a Marine Corps Marathon (MCM) Charity Partner! BCAN has been allocated 25 guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013; an event that sold out in 2 hours and 41 minutes in 2012.
  • We are looking at building “Team BCAN” to not only run in the event and raise awareness for bladder cancer but to raise needed funds for fostering research and patient education. According to the Marine Corps Marathon, there is not a required qualifying time to participate in the event, but all runners should maintain at least a 14 minute mile pace. In order to become a member of “Team BCAN” and officially have a slot in this year’s race, you must be registered through BCAN.
  • No federal or Marine Corps endorsement is implied.
  • If you are interested in becoming a member of BCAN’s team or have any questions, please contact Larry Rzepka, BCAN’s Executive Director, at lrzepka@bcan.org.
  • David McConkey, Ph.D.
    Dr. David J. McConkey is a Professor of Urology and Cancer Biology, Director for Urological Research, and
    Deputy Division Head for Research (Surgery) at the University of Texas M.D. Anderson Cancer Center. Dr.
    McConkey was born in Buffalo, New York but moved to Minneapolis soon afterward. He received his BA
    in Biochemistry and American History from Brown University and his PhD from the Karolinska Institute
    in Stockholm. He performed postdoctoral studies in immunobiology at the Dana-Farber Cancer Institute
    before accepting a tenure-track position at MD Anderson in 1993. He has been studying the biochemistry and
    molecular regulation of apoptosis since he was a graduate student, but more recently his work has focused
    on translational cancer research and the mechanisms of action of experimental therapeutics, particularly
    inhibitors of the proteasome and the epidermal growth factor receptor (EGFR) and TNF-related apoptosis-
    inducing ligand (TRAIL). Dr. McConkey has published over 150 papers in peer-reviewed journals and is a
    Project Leader on two Specialized Programs of Research Excellence (SPORE) grants (in bladder and pancreatic
    cancer). Dr. McConkey is on the editorial boards of Clinical Cancer Research and the Journal of Biological
    Chemistry and serves as a regular member of peer review panels for NCI and the Damon-Runyon Cancer
    Research Foundation. He is a member of several professional organizations including the American Urological
    Association, the Society for Basic Urological Research, the American Society of Clinical Oncology, the
    American Association for Cancer Research, and the American Society of Biochemistry and Molecular Biology,
    and he is co-chair for translational research in the genitourinary tumors subgroup of the Southwest Oncology
    Group.

    McConkey

    David McConkey, M.D., Ph.D.

    Dr. David J. McConkey is a Professor of Urology and Cancer Biology, Director for Urological Research, and Deputy Division Head for Research (Surgery) at the University of Texas M.D. Anderson Cancer Center.  Dr. McConkey was born in Buffalo, New York but moved to Minneapolis soon afterward.  He received his BA in Biochemistry and American History from Brown University and his PhD from the Karolinska Institute in Stockholm.  He performed postdoctoral studies in immunobiology at the Dana-Farber Cancer Institute before accepting a tenure-track position at MD Anderson in 1993.  He has been studying the biochemistry and molecular regulation of apoptosis since he was a graduate student, but more recently his work has focused on translational cancer research and the mechanisms of action of experimental therapeutics, particularly inhibitors of the proteasome and the epidermal growth factor receptor (EGFR) and TNF-related apoptosis-inducing ligand (TRAIL).  Dr. McConkey has published over 150 papers in peer-reviewed journals and is a Project Leader on two Specialized Programs of Research Excellence (SPORE) grants (in bladder and pancreatic cancer).  Dr. McConkey is on the editorial boards of Clinical Cancer Research and the Journal of Biological Chemistry and serves as a regular member of peer review panels for NCI and the Damon-Runyon Cancer Research Foundation.  He is a member of several professional organizations including the American Urological Association, the Society for Basic Urological Research, the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society of Biochemistry and Molecular Biology, and he is co-chair for translational research in the genitourinary tumors subgroup of the Southwest Oncology Group.